Literature DB >> 35254477

Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma.

Li-Hua Qu1, Qian Fang1, Tong Yin1, Hui-Mei Yi2, Guang-Bo Mei1, Zi-Zhan Hong1, Xue-Bing Qiu3, Rui Zhou4, Hui-Fen Dong5.   

Abstract

BACKGROUND: Histone lysine demethylases (KDMs) are closely related to the occurrence and development of different tumors through epigenetic mechanisms. However, the prognosis and immune infiltration of KDMs in hepatocellular carcinoma (HCC) remain undefined.
METHODS: In the current study, we analyzed the expression of KDMs on HCC patients using the Oncomine, GEPIA, UALCAN, Kaplan-Meier Plotter, cBioPortal, GeneMANIA, STRING, Metascape, GSEA, and TIMER databases. Finally, we investigated KDM expression in HCC by qRT-PCR, Western blotting, and IHC.
RESULTS: We found that KDM3A/3B/5A/5B and KDM6A were upregulated in HCC patients, while KDM6B and KDM8 were downregulated. The high expressions of KDM1A/2B/3B/5B/5C were markedly related to tumor stages and grades of HCC patients. The abnormal expression of KDM1A/1B/3A/4A/5A/5C/6A/6B/7A and KDM8 were associated with HCC patients' prognosis. Also, we found that HCC tissues presented higher expression levels of KDM1A/2A/5A/5B and lower expression levels of KDM6B. The function of KDMs was primarily related to the histone demethylase activity and cell cycle, p53 signaling pathway, pathways in cancer, transcriptional mis-regulation in cancer, viral carcinogenesis, and FoxO signaling pathway. Furthermore, we indicated that the pathways most involved were the mitotic spindle and DNA repair. Additionally, we found that the expression of KDM1A/1B/3A/4A/5B/5C and KDM6A were significantly correlated with HCC immune infiltration.
CONCLUSIONS: Overall, our current results indicated that KDM1A/1B/3A/4A/5B/5C and KDM6A could be novel prognostic biomarkers and provide insights into potential immunotherapy targets to HCC patients.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Hepatocellular carcinoma; Histone lysine demethylases; Immune infiltrates; Prognosis biomarker

Mesh:

Substances:

Year:  2022        PMID: 35254477     DOI: 10.1007/s00262-022-03167-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.630


  58 in total

1.  Lysine Demethylase LSD1 Coordinates Glycolytic and Mitochondrial Metabolism in Hepatocellular Carcinoma Cells.

Authors:  Akihisa Sakamoto; Shinjiro Hino; Katsuya Nagaoka; Kotaro Anan; Ryuta Takase; Haruka Matsumori; Hidenori Ojima; Yae Kanai; Kazunori Arita; Mitsuyoshi Nakao
Journal:  Cancer Res       Date:  2015-02-03       Impact factor: 12.701

2.  Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming.

Authors:  Margaret E McLaughlin-Drubin; Christopher P Crum; Karl Münger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-18       Impact factor: 11.205

3.  Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.

Authors:  T Nakatsuka; K Tateishi; Y Kudo; K Yamamoto; H Nakagawa; H Fujiwara; R Takahashi; K Miyabayashi; Y Asaoka; Y Tanaka; H Ijichi; Y Hirata; M Otsuka; M Kato; J Sakai; M Tachibana; H Aburatani; Y Shinkai; K Koike
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

Review 4.  The ageing epigenome and its rejuvenation.

Authors:  Weiqi Zhang; Jing Qu; Guang-Hui Liu; Juan Carlos Izpisua Belmonte
Journal:  Nat Rev Mol Cell Biol       Date:  2020-02-04       Impact factor: 94.444

5.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

6.  Histone lysine demethylases in breast cancer.

Authors:  Elisa Paolicchi; Francesco Crea; William L Farrar; Jeffrey E Green; Romano Danesi
Journal:  Crit Rev Oncol Hematol       Date:  2012-12-23       Impact factor: 6.312

Review 7.  Epidemiology of Hepatocellular Carcinoma.

Authors:  Katherine A McGlynn; Jessica L Petrick; Hashem B El-Serag
Journal:  Hepatology       Date:  2020-11-24       Impact factor: 17.298

Review 8.  Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma.

Authors:  Mohamed H Yousef; Hassan A N El-Fawal; Anwar Abdelnaser
Journal:  Biomed Res Int       Date:  2020-11-24       Impact factor: 3.411

9.  NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.

Authors:  Chi Ma; Aparna H Kesarwala; Tobias Eggert; José Medina-Echeverz; David E Kleiner; Ping Jin; David F Stroncek; Masaki Terabe; Veena Kapoor; Mei ElGindi; Miaojun Han; Angela M Thornton; Haibo Zhang; Michèle Egger; Ji Luo; Dean W Felsher; Daniel W McVicar; Achim Weber; Mathias Heikenwalder; Tim F Greten
Journal:  Nature       Date:  2016-03-02       Impact factor: 49.962

Review 10.  Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges.

Authors:  Yuchen Chen; Xinran Liu; Yangkai Li; Chuntao Quan; Ling Zheng; Kun Huang
Journal:  Comput Struct Biotechnol J       Date:  2018-06-20       Impact factor: 7.271

View more
  1 in total

1.  Application of two-dimensional difference gel electrophoresis to identify protein changes between center, margin, and adjacent non-tumor tissues obtained from non-small-cell lung cancer with adenocarcinoma or squamous cell carcinoma subtype.

Authors:  Andrzej Ciereszko; Mariola A Dietrich; Mariola Słowińska; Joanna Nynca; Michał Ciborowski; Monika M Kaczmarek; Kamil Myszczyński; Joanna Kiśluk; Anna Majewska; Anna Michalska-Falkowska; Natalia Kodzik; Joanna Reszeć; Ewa Sierko; Jacek Nikliński
Journal:  PLoS One       Date:  2022-05-05       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.